Table 4.
Common TEAEs (≥3% in any treatment group) in the PBO-controlled period up to week 12
| FIL 200 mg N=777 |
FIL 100 mg N=788 |
PBO N=781 |
|
| Nasopharyngitis, n (%) | 27 (3.5) | 19 (2.4) | 19 (2.4) |
| Upper respiratory tract infection, n (%) | 26 (3.3) | 20 (2.5) | 14 (1.8) |
| Nausea, n (%) | 27 (3.5) | 18 (2.3) | 13 (1.7) |
FIL, filgotinib; PBO, placebo; TEAE, treatment-emergent adverse event.